Xenon Pharmaceuticals Inc. Contracts & Agreements

Amended and Restated 2014 Equity Incentive Plan and form of share option agreement used thereunder (Filed With SEC on June 5, 2024)

Form of Performance Share Award Agreement (Filed With SEC on May 9, 2024)

Employment Agreement, dated December 15, 2023, by and between the Company and James Empfield (Filed With SEC on February 29, 2024)

Consent to Alterations Agreement between Redstone Enterprises Ltd. and Xenon Pharmaceuticals Inc., effective August 16, 2023 (Filed With SEC on February 29, 2024)

Description of Securities (Filed With SEC on February 29, 2024)

Form of Pre-Funded Warrant (Filed With SEC on November 30, 2023)

Underwriting Agreement, dated November 29, 2023, among Xenon Pharmaceuticals Inc., J.P. Morgan Securities LLC, Jefferies LLC, BofA Securities, Inc., Stifel, Nicolaus & Company,... (Filed With SEC on November 30, 2023)

Consent to Alterations Agreement between Redstone Enterprises Ltd. and Xenon Pharmaceuticals Inc., effective March 27, 2023 (Filed With SEC on August 9, 2023)

Employment Agreement, dated November 7, 2022, by and between the Company and Andrea DiFabio (Filed With SEC on November 8, 2022)

Consent to Alterations and Lease Modification Agreement between Redstone Enterprises Ltd. and Xenon Pharmaceuticals Inc., effective May 19, 2022 (Filed With SEC on August 9, 2022)

Form of Pre-Funded Warrant (Filed With SEC on June 23, 2022)

Underwriting Agreement, dated June 22, 2022, among Xenon Pharmaceuticals Inc., Jefferies LLC, J.P. Morgan Securities LLC, SVB Securities LLC and Stifel, Nicolaus & Company,... (Filed With SEC on June 23, 2022)

Amended and Restated 2014 Equity Incentive Plan and form of share option agreement used thereunder (Filed With SEC on June 2, 2022)

Amendment No. 1 to the At-the-Market Equity Offering Sales Agreement, dated March 1, 2022, by and among Xenon Pharmaceuticals Inc., Jefferies LLC and Stifel, Nicolaus & Company,... (Filed With SEC on March 1, 2022)

Amendment #2, dated February 25, 2022, to the License and Collaboration Agreement, dated December 2, 2019, by and between Xenon Pharmaceuticals Inc. and Neurocrine Biosciences, Inc (Filed With SEC on March 1, 2022)

Share Purchase Agreement, dated as of January 11, 2022, by and between Xenon Pharmaceuticals Inc. and Neurocrine Biosciences, Inc (Filed With SEC on January 12, 2022)

Lease Agreement, dated as of November 24, 2021, by and between the Company and Redstone Enterprises Ltd (Filed With SEC on December 1, 2021)

Employment Agreement, dated August 18, 2021, by and between the Company and Christopher Kenney (Filed With SEC on November 10, 2021)

Underwriting Agreement, dated October 5, 2021, among Xenon Pharmaceuticals Inc., Jefferies LLC, SVB Leerink LLC, and Stifel, Nicolaus & Company, Incorporated, as representatives... (Filed With SEC on October 6, 2021)

Form of Pre-Funded Warrant (Filed With SEC on October 6, 2021)

Share Purchase Agreement, dated as of September 8, 2021, by and between Xenon Pharmaceuticals Inc. and Neurocrine Biosciences, Inc (Filed With SEC on September 8, 2021)

Termination Agreement, dated August 6, 2021, by and among Xenon Pharmaceuticals Inc., Genentech, Inc. and F. Hoffmann-La Roche Ltd (Filed With SEC on August 11, 2021)

Underwriting Agreement, dated March 9, 2021, among Xenon Pharmaceuticals Inc., Jefferies LLC and Stifel, Nicolaus & Company, Incorporated, as representatives of the several... (Filed With SEC on March 10, 2021)

Form of Pre-Funded Warrant (Filed With SEC on March 10, 2021)

Form of Share Option Agreement, as amended, under the Amended and Restated 2014 Equity Incentive Plan (Filed With SEC on March 1, 2021)

Lease Modification Agreement, effective October 5, 2020, by and between the Company and Redstone Enterprises Ltd (Filed With SEC on March 1, 2021)

Amendment #1, dated January 13, 2021, to the License and Collaboration Agreement, dated December 2, 2019, by and between Xenon Pharmaceuticals Inc. and Neurocrine Biosciences, Inc (Filed With SEC on January 14, 2021)

Employment Agreement, dated January 13, 2021, by and between the Company and Ian Mortimer (Filed With SEC on January 14, 2021)

Employment Agreement, dated January 13, 2021, by and between the Company and Simon Pimstone (Filed With SEC on January 14, 2021)

Employment Agreement, dated January 13, 2021, by and between the Company and Sherry Aulin (Filed With SEC on January 14, 2021)

Employment Agreement, dated July 17, 2020, by and between the Company and Christopher Von Seggern (Filed With SEC on November 5, 2020)

Amendment to Asset Purchase Agreement, dated August 4, 2020, by and between the Company and 1st Order Pharmaceuticals, Inc (Filed With SEC on August 6, 2020)

At-the-Market Equity Offering Sales Agreement dated as of August 6, 2020, by and among Xenon Pharmaceuticals Inc., Jefferies LLC and Stifel, Nicolaus & Company, Incorporated (Filed With SEC on August 6, 2020)

Amended and Restated 2014 Equity Incentive Plan and form of share option agreement used thereunder (Filed With SEC on June 3, 2020)

Description of Securities (Filed With SEC on March 9, 2020)

Amended and Restated Employment Agreement, dated March 20, 2019, by and between the Company and James Empfield (Filed With SEC on March 9, 2020)

Amended and Restated Employment Agreement, dated March 19, 2019, by and between the Company and Robin Sherrington (Filed With SEC on March 9, 2020)

Underwriting Agreement, dated January 22, 2020, among Xenon Pharmaceuticals Inc., Jefferies LLC, Stifel, Nicolaus & Company, Incorporated, and Guggenheim Securities, LLC as... (Filed With SEC on January 23, 2020)

At-the-Market Equity Offering Sales Agreement dated as of November 5, 2019, by and among Xenon Pharmaceuticals Inc., Jefferies LLC and Stifel, Nicolaus & Company, Incorporated (Filed With SEC on November 5, 2019)

2019 Inducement Equity Incentive Plan and related form of share option agreement (Filed With SEC on September 10, 2019)

Amended and Restated Employment Agreement, dated March 19, 2019, by and between the Company and Ian Mortimer (Filed With SEC on March 25, 2019)

Amended and Restated Employment Agreement, dated March 19, 2019, by and between the Company and Simon Pimstone (Filed With SEC on March 25, 2019)

Amended and Restated Employment Agreement, dated March 19, 2019, by and between the Company and Ernesto Aycardi (Filed With SEC on March 25, 2019)

Form of Offer of Employment (CDN Executive) (Filed With SEC on March 25, 2019)

Form of Amended and Restated Employment Agreement (CDN Executive) (Filed With SEC on March 25, 2019)

Form of Offer of Employment (U.S. Executive) (Filed With SEC on March 25, 2019)

Form of Amended and Restated Employment Agreement (U.S. Executive) (Filed With SEC on March 25, 2019)

Amended and Restated Amendment #7, dated September 27, 2018, to the Collaborative Research and License Agreement, dated December 22, 2011, by and among the Company, Genentech,... (Filed With SEC on November 6, 2018)

Underwriting Agreement, dated September 12, 2018, among Xenon Pharmaceuticals, Inc., Jefferies LLC and Stifel, Nicolaus & Company, Incorporated, as representatives of the several... (Filed With SEC on September 13, 2018)

Milestone and Royalty Buy-Out Agreement, dated September 7, 2018, by and among Xenon Pharmaceuticals Inc., Valeant Pharmaceuticals Ireland Limited and Valeant Pharmaceuticals... (Filed With SEC on September 11, 2018)

Warrant to Purchase Shares, dated August 3, 2018, by and between Xenon Pharmaceuticals Inc. and Silicon Valley Bank (Filed With SEC on August 7, 2018)

Letter Amendment #7, dated July 25, 2018, to the Collaborative Research and License Agreement, dated December 22, 2011, by and among the Company, Genentech, Inc. and F.... (Filed With SEC on August 7, 2018)

Amended and Restated Loan and Security Agreement, dated August 3, 2018, by and among Xenon Pharmaceuticals Inc., Xenon Pharmaceuticals USA Inc. and Silicon Valley Bank (Filed With SEC on August 7, 2018)

At-the-Market Equity Offering Sales Agreement, dated as of July 11, 2018, by and among Xenon Pharmaceuticals Inc., Jefferies LLC and Stifel, Nicolaus & Company, Incorporated (Filed With SEC on July 12, 2018)

First Loan Modification to Loan and Security Agreement, dated June 12, 2018, by and among Xenon Pharmaceuticals Inc., Xenon Pharmaceuticals USA Inc. and Silicon Valley Bank (Filed With SEC on June 13, 2018)

At-the-Market Equity Offering Sales Agreement, dated as of May 8, 2018, between Xenon Pharmaceuticals Inc. and Stifel, Nicolaus & Company, Incorporated (Filed With SEC on May 8, 2018)

Specimen Series 1 Preferred Share Certificate (Filed With SEC on March 28, 2018)

Exchange Agreement, dated March 23, 2018, by and among the Company and the shareholders listed in Schedule B thereto (Filed With SEC on March 28, 2018)

Termination Agreement by and among Xenon Pharmaceuticals Inc., Teva Pharmaceuticals International GmbH and Teva Canada Limited dated March 7, 2018 (Filed With SEC on March 7, 2018)

Loan and Security Agreement, dated December 18, 2017, by and among Xenon Pharmaceuticals Inc., Xenon Pharmaceuticals USA Inc. and Silicon Valley Bank (Filed With SEC on December 18, 2017)

Warrant to Purchase Shares, dated December 18, 2017, by and between Xenon Pharmaceuticals Inc. and Silicon Valley Bank (Filed With SEC on December 18, 2017)

SHARE OPTION AGREEMENT (Filed With SEC on March 8, 2017)

APPENDIX A ADDITIONAL TERMS TO EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on March 8, 2017)

4,000,000 Shares XenonPharmaceuticals Inc. UNDERWRITING AGREEMENT (Filed With SEC on September 9, 2016)

LEASE MODIFICATION AGREEMENT (Filed With SEC on March 8, 2016)

Appendix A Xenon Pharmaceuticals Inc., & Genentech, Inc., Research Plan November 9, 2015 (Filed With SEC on March 8, 2016)

LEASE MODIFICATION AGREEMENT (Filed With SEC on November 10, 2015)

ScheduleA-1 NaV1.6 (Filed With SEC on August 13, 2015)

EXCLUSIVE COLLABORATIVE RESEARCH AND OPTION AGREEMENT by and between MERCKSHARP & DOHME RESEARCH LTD. and XENON PHARMACEUTICALS INC. (Filed With SEC on October 6, 2014)

XENON PHARMACEUTICALS INC. and GENENTECH, INC. and F.HOFFMANN-LA ROCHE LTD COLLABORATIVE RESEARCH AND LICENSE AGREEMENT DECEMBER 22, 2011 (Filed With SEC on October 6, 2014)

XENON PHARMACEUTICALS INC. and IVAX INTERNATIONAL GMBH COLLABORATIVE DEVELOPMENT AND LICENSE AGREEMENT Effective as of December 7, 2012 (Filed With SEC on October 6, 2014)

[] Shares Xenon Pharmaceuticals Inc. UNDERWRITING AGREEMENT (Filed With SEC on October 6, 2014)

AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (Filed With SEC on October 6, 2014)

XENON PHARMACEUTICALS INC. AMENDED AND RESTATED STOCK OPTION PLAN (Filed With SEC on October 6, 2014)

LICENSE AGREEMENT (Filed With SEC on October 6, 2014)

SUBLICENSE AND RESEARCH AGREEMENT (Filed With SEC on October 6, 2014)

INDEMNIFICATION AGREEMENT BETWEEN XENONPHARMACEUTICALS INC. AND MADE AS OF , 2014 INDEMNIFICATION AGREEMENT, (Filed With SEC on October 6, 2014)

SCHEDULE A Disclosure of Volunteer, Board and Other External Commitments (Filed With SEC on October 6, 2014)

XENON PHARMACEUTICALS INC. COMMON SHARE PUT AGREEMENT March 19, 2014 XENON PHARMACEUTICALS INC. COMMON SHARE PUT AGREEMENT (Filed With SEC on September 10, 2014)

TABLE OF CONTENTS (Filed With SEC on September 10, 2014)

2014 EQUITY INCENTIVE PLAN XENON PHARMACEUTICALS INC. ARTICLE 1 PURPOSE (Filed With SEC on September 10, 2014)

XENON PHARMACEUTICALS INC. AMENDED AND RESTATED STOCK OPTION PLAN (Filed With SEC on September 10, 2014)

Consulting Agreement (Filed With SEC on September 10, 2014)

Category

Industry

Companies

Contracts

Xenon Pharmaceuticals Inc. Contracts & Agreements